Clinical Trial Update: IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing the safety, tolerability, and immunogenicity of IPV-102 (TAK-195) in healthy infants, toddlers, and adults was terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• IPV-102 (TAK-195)

Snippet

Sponsor: Takeda | Conditions: Poliomyelitis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-01-31